Sage Therapeutic Stock Price, News & Analysis

Zuranolone 50 mg has shown improvement in depressive symptoms by Day 15 in the SKYLARK Study, with statistically significant results also at Days 3, 28, and 45. The study, presented at the ECNP Congress, highlighted the drug's rapid effect in women suffering from postpartum depression (PPD). Zuranolone was well-tolerated, with mild to moderate treatment-emergent adverse events. A New Drug Application (NDA) submission to the FDA for zuranolone is underway, aiming for completion in late 2022.

Sage Therapeutics and Biogen present new analyses on zuranolone, an investigational treatment for major depressive disorder (MDD) and postpartum depression (PPD), at Psych Congress in New Orleans from September 17 to 20, 2022. Key findings from the SHORELINE Study show a median of 135 days for repeat treatment in the 30 mg cohort. Results indicate sustained improvements in MDD symptoms and a favorable safety profile. Zuranolone is being evaluated under Fast Track and Breakthrough Therapy Designations by the FDA.

Sage Therapeutics, Inc. (Nasdaq: SAGE) has announced its presentation at the Morgan Stanley 20th Annual Global Healthcare Conference on September 12, 2022, at 3:40 p.m. ET in New York, NY. Investors can access a live webcast on the Company’s investor page, with a replay available two hours post-event and archived for 30 days. Sage Therapeutics focuses on pioneering solutions for brain health medicines, aiming to enhance the quality of life for individuals.

Sage Therapeutics reported Q2 2022 results, highlighting progress on the rolling NDA submission for zuranolone aimed at treating major depressive disorder (MDD) and postpartum depression (PPD). The company announced positive topline data from the Phase 3 SKYLARK Study for PPD and is enrolling multiple Phase 2 studies across neuropsychiatry and neurology. Despite a net loss of $126.3 million, the company expects its financial position to support operations into 2025. Sage anticipates cash and marketable securities of approximately $1.3 billion by year-end 2022.

Sage Therapeutics (Nasdaq: SAGE) announced its participation in two upcoming investor conferences in August 2022. The company will hold a fireside chat at the Wedbush PacGrow Healthcare Conference on Tuesday, August 9, 2022, at 9:00 a.m. ET, and at the Canaccord Genuity 42nd Annual Growth Conference in Boston, MA, on Wednesday, August 10, 2022, at 10:00 a.m. ET. Live webcasts will be accessible on Sage's investor page with replays available for 30 days.

Sage Therapeutics, Inc. (Nasdaq: SAGE) announced a live webcast on August 2, 2022, at 8:00 a.m. ET to disclose its second quarter 2022 financial results and discuss recent business updates. Investors can access the webcast via the company's investor page. A replay will be available for 30 days post-event.

Sage Therapeutics, a biopharmaceutical company focused on brain health, announced its participation in two key investor conferences in June 2022. The Jefferies Healthcare Conference will feature a fireside chat on June 8 at 11:30am ET in New York, while the Goldman Sachs Annual Global Healthcare Conference is set for June 13 at 3:20pm PT (6:20pm ET) in Palos Verdes, CA. Live webcasts of both events can be accessed on Sage's investor website, with replays available afterward for 30 days.

Sage Therapeutics and Biogen announced successful results from the Phase 3 SKYLARK Study of zuranolone, an oral treatment for postpartum depression (PPD). The study achieved its primary endpoint, showing a statistically significant improvement in depressive symptoms at Day 15 with a change from baseline HAMD-17 total score of -15.6 for zuranolone compared to -11.6 for placebo (p=0.0007). Additionally, safety profiles were consistent with previous studies. Zuranolone aims to provide rapid relief for the one in eight women affected by PPD in the U.S.

Sage Therapeutics (NASDAQ: SAGE) announced its participation in the Bank of America Securities 2022 Healthcare Conference, scheduled for May 11, 2022, at 8:00am PT (11:00am ET) in Las Vegas, NV. The presentation will be accessible via a live webcast on Sage's investor page. A replay will be available two hours post-event and archived for 30 days. Sage Therapeutics is committed to pioneering brain health solutions aimed at enhancing overall well-being. For further details, visit www.sagerx.com.